Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s Arcoxia should not be approved based on a comparison to diclofenac in the MEDAL studies, Cleveland Clinic’s Nissen says.